SHR3591 / Jiangsu Hengrui Pharma - LARVOL DELTA

Discovery of SHR3591, a highly potent and orally bioavailable AR PROTAC for the treatment of prostate cancer (AACR 2025) - "A number of AR-centered therapies have been developed for the treatment of prostate cancer, such as CYP17A1 inhibitor abiraterone, which blocks the androgen synthesis pathway, and a series of second-generation AR antagonists. SHR3591 showed favorable pharmacokinetic profiles across different preclinical species as well. SHR3591 has advanced into phase1/1b clinical studies in patients with mCRPC."

Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Lung Cancer • Oncology • Prostate Cancer • Solid Tumor • CRBN • GSPT1 • IKZF1 • IKZF3